Biocryst Pharmaceuticals Inc.

NASDAQ: BCRX    
Share price (5/3/24): $4.48    
Market cap (5/3/24): $924 million
Search in Documents
Key Exhibits
External Links
8 Biocryst Pharmaceuticals Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.2
from 10-Q 13 pages Biocryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan
12/34/56
EX-10.3
from 10-Q 8 pages Biocryst Pharmaceuticals, Inc. Employee Stock Purchase Plan
12/34/56
EX-10.1
from 10-Q 112 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. in Addition, Certain Personally Identifiable Information Contained in This Document, Marked “[***]” Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K
12/34/56
EX-10.1
from 8-K 23 pages Biocryst Pharmaceuticals, Inc. Stock Incentive Plan
12/34/56
EX-10.25
from 10-K 5 pages Biocryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan Notice of Restricted Stock Unit Award
12/34/56
EX-10.4
from 10-Q 2 pages First Amendment to Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.5
from 10-Q 2 pages Material contract
12/34/56
EX-10.4
from 10-Q 4 pages Biocryst Pharmaceuticals, Inc. Stock Incentive Plan Notice of Grant of Non-Employee Director Restricted Stock Unit Award
12/34/56
EX-10.3
from 10-Q 5 pages Biocryst Pharmaceuticals, Inc. Notice of Grant of Non-Employee Director Stock Option
12/34/56
EX-10.1
from 8-K 17 pages Biocryst Pharmaceuticals, Inc. Stock Incentive Plan
12/34/56
EX-10.2
from 10-Q 3 pages Biocryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Effective April 18, 2022
12/34/56
EX-10.1
from 10-Q 2 pages Material contract
12/34/56
EX-10.104
from 10-K 16 pages Certain Personally Identifiable Information Has Been Omitted From This Exhibit in Places Marked “[***]” Pursuant to Item 601(a)(6) Under Regulation S-K. Biocryst Pharmaceuticals, Inc. Common Stock Purchase Agreement
12/34/56
EX-10.103
from 10-K 56 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. in Addition, Certain Personally Identifiable Information Contained in This Document, Marked “[***]” Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. Purchase and Sale Agreement by and Between Biocryst Pharmaceuticals, Inc. and Ocm Ip Healthcare Holdings Limited Dated as of November 19, 2021
12/34/56
EX-10.102
from 10-K 62 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. in Addition, Certain Personally Identifiable Information Contained in This Document, Marked “[***]” Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. 2021 Purchase and Sale Agreement by and Between Biocryst Pharmaceuticals, Inc. and Rpi 2019 Intermediate Finance Trust Dated as of November 19, 2021
12/34/56
EX-10.76
from 10-K 2 pages Material contract
12/34/56
EX-10.72
from 10-K 1 page Material contract
12/34/56
EX-10.14
from 10-K 6 pages Biocryst Pharmaceuticals, Inc. Stock Incentive Plan Notice of Restricted Stock Unit Award
12/34/56
EX-10.10
from 10-Q 2 pages First Amendment to Employment Agreement
12/34/56